A Plus Biotechnology Co Ltd
6918.TW
Taiwan Stock Exchange68.80
TWD
-1.30
- -
ISIN
TW0006918006
Return %
Stock
S&P500
1Y
-30.29
16.61
3Y
48.60
61.62
5Y
37.05
68.72
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Kai Hsing Wu
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- No.21, Qiaohe Rd New Taipei Taiwan, Province of China 235
- IPO Date
- Jan 6, 2023
- Website
- aplusbio.com
- Similar Companies
- Business
- A Plus Biotechnology Co Ltd, a Taiwanese biopharmacy and life sciences company, specializes in the development, manufacture, and sale of therapeutic and research-grade biotech products and related services for life science research, diagnostics, and pharmaceutical applications. The company focuses on enabling drug discovery, preclinical and clinical research, and applied molecular biology through its portfolio of products, platforms, and contract research capabilities. A Plus Biotechnology coalesces core offerings around biological reagents, cell-based assay systems, diagnostic tools, and related biotech consumables, supported by technical services, custom assay development, and contract research collaboration. Main Products and Services: - Core product categories: recombinant proteins and proteins and enzymes for research use; monoclonal and polyclonal antibodies and antibody-related reagents; viral vectors and gene delivery systems; diagnostic kits and assay reagents; cell culture media, sera, and supplements; molecular biology reagents including nucleic acid isolation kits, PCR/qPCR reagents, and cloning systems; biosensors and diagnostic readouts; biotech consumables such as tubes, plates, and pipette tips; software and data analysis services for bioassays and genomics workflows. - Product brands and lineups: branded lines across recombinant proteins, antibody repertoires, and diagnostic assay components; specialized assay platforms and complementary reagent ecosystems designed for life science research, translational medicine, and clinical laboratory applications. - Services and platforms: contract research and development services for assay development, biomarker validation, and preclinical testing; custom manufacture and scale-up of biotech reagents; assay optimization, analytical testing, and quality control; data analysis, bioinformatics support, and assay qualification services; technical support, training, and method transfer to customer laboratories. Latest Major Company Changes: - Strategic partnerships: enters alliances with academic and industry partners to co-develop diagnostic assays and therapeutic discovery platforms; expands collaboration with contract research organizations to broaden service offerings and geographic reach. - Financing and ownership: completes recent financing rounds and expands investor base to support capacity expansion, GMP capability upgrades, and pipeline advancement; realigns corporate structure to support international growth. - Product launches and offerings: launches new diagnostic assay kits and expanded reagent portfolios for molecular diagnostics, infectious disease panels, and oncology biomarker applications; introduces enhanced cell culture systems and bioprocess-compatible reagents for scalable research and manufacturing workflows. - Strategic shifts and expansions: accelerates global market expansion through regional manufacturing hubs and distribution networks; augments R&D with investment in gene therapy tooling, next-generation sequencing workflows, and high-throughput screening capabilities. - Corporate reorganizations: implements organizational realignments to streamline product development, regulatory affairs, and global sales; rebrands specific product lines to reflect enhanced capabilities and compliance standards. - Operational changes: expands manufacturing footprint, upgrades QC and GMP systems within the last 1-2 years; enhances supply chain resilience with diversified supplier bases and logistics partnerships. Additional Context: - Industry and segments: life sciences tools, biotechnology reagents, molecular biology, diagnostics, contract research and development services. - Target markets: academic laboratories, pharmaceutical and biotechnology companies, clinical diagnostic laboratories, and contract research organizations. - Geographic operations: operates across Taiwan with distribution and sales networks in Asia-Pacific and global markets; maintains manufacturing presence in selected regions to serve international customers. - Founding year and headquarters: established in the early 2000s; headquartered in Taiwan. - Subsidiaries and parent relationships: operates as a standalone public private enterprise with potential affiliations to regional distributors and a network of contract research partners; maintains subsidiary-style entities or partners to support regional sales and service delivery.